---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-043170"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-11-30T23:59:59+00:00"
generated_at: "2026-06-07T20:03:24.809397+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ZyVersa Therapeutics approves 1-for-35 reverse stock split and increases authorized shares to 251M

## Summary
- Reverse split 1:35 effective Dec 4, 2023 at 4:01 pm ET; adjusted trading begins Dec 5 under ZVSA.
- Authorized common shares increased from 110M to 250M; total capital stock from 111M to 251M.
- Split intended to meet Nasdaq's $1.00 minimum bid price requirement for continued listing.
- No fractional shares will be issued; holders will receive rounding to nearest whole share.
- Proportional adjustments to equity awards, warrants, and convertible securities.

## SEC filing metadata
- accession: 0001493152-23-043170
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-11-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223043170/0001493152-23-043170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223043170/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-043170
- JSON: https://secwatch.observer/filing/0001493152-23-043170.json
- Plain text: https://secwatch.observer/filing/0001493152-23-043170.txt

## Key facts
- Governance Changes
  ZyVersa Therapeutics, Inc.: Certificate of amendment to effect a 1-for-35 reverse stock split and increase authorized capital stock from 111,000,000 to 251,000,000 shares (effective 2023-12-04).
  - Change: charter amendment
  - Effective: 2023-12-04
  source text: On November 30, 2023, ZyVersa Therapeutics, Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware relating to a 1-for-35 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223043170/0001493152-23-043170-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.